Molecular Analysis of Thrombocytopenia and Cancer (MATAC): Investigating Antigenic Mimicry Between Platelets and Tumor Cells in Patients With Immune Thrombocytopenia (ITP) Associated With Cancer (MATAC)

January 22, 2026 updated by: University Hospital, Bordeaux
The association between hematologic malignancies and ITP is well described, but this link is much less clear with solid cancers. In cases of ITP associated with cancers, specific cancer treatment can lead to remission or even cure of ITP. Thus, our hypothesis was that chronic expression of GPIIB by tumor cells could have initiated an autoimmune loop against GPIIB, leading to the onset and perpetuation of ITP.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Autoimmune thrombocytopenia, also known as immune thrombocytopenic purpura (ITP), is a rare autoimmune disease characterized by platelet destruction and impaired production, posing a life-threatening risk due to bleeding complications. The pathophysiology of ITP involves complex mechanisms, including both defective platelet production and auto-reactivity of B and T lymphocytes leading to the production of autoantibodies against platelets, found in 35 to 55% of cases. Additionally, in the context of neoplasia, some patients may develop varying degrees of thrombocytopenia, exacerbating morbidity and mortality. A multicenter, retrospective study will collect data from routine care, including birth date, gender, biological parameters related to ITP, dates of treatment initiation and diagnosis of ITP and cancer, types of treatments, and outcomes such as survival or death, without additional medical interventions or appointments.

Study Type

Observational

Enrollment (Actual)

33

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Bondy, France
        • AP-HP Hôpital Jean Verdier service de médecine interne
      • Clermont-Ferrand, France
        • CHU de Clermont-Ferrand - service de médecine interne
      • Créteil, France
        • AP-HP Hôpital Mondor service de médecine interne
      • Le Kremlin-Bicêtre, France
        • AP-HP Hôpital Bicêtre service de médecine interne
      • Lille, France
        • CHU de Lille - service d'Hématologie
      • Lyon, France
        • HCL - service d'Hématologie
      • Marseille, France
        • AP-HM Hôpital la Timone - service de médecine interne
      • Montpellier, France
        • CHU de Montpellier - service d'Hématologie
      • Nancy, France
        • CHRU de Nancy - service de Médecine Interne et Immunologie Clinique
      • Nantes, France
        • CHU de Nantes - Service de Médecine interne
      • Orléans, France
        • CHRU d'Orléans - service de Médecine interne
      • Orléans, France
        • CHRU d'Orléans - service de réanimation
      • Paris, France
        • AP-HP Hôpital Bichat service de médecine interne
      • Paris, France
        • AP-HP Hôpital Saint-Antoine service de médecine interne
      • Paris, France
        • AP-HP Hôpital Saint-Louis service immuno-hématologie
      • Pessac, France
        • CHU de Bordeaux Service de Médecine Interne et Maladies Infectieuses
      • Poitiers, France
        • CHU de Poitiers - service de médecine interne
      • Strasbourg, France
        • CHRU de Strasbourg - service de médecine interne
      • Toulouse, France
        • CHU de Toulouse - service de médecine interne
      • Tours, France
        • CHU de Tours - service de médecine interne

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients with a definite diagnosis of both ITP and cancer

Description

Inclusion Criteria:

  • Adult patients with a definite diagnosis of both ITP and cancer;
  • Synchronous diagnosis of ITP and cancer;
  • Onset of ITP occurring 6 months before or after the diagnosis of cancer.

Exclusion Criteria:

  • None

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Patients with a definite diagnosis of both ITP and cancer
Other: ITP and cancer
ITP and cancer

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Remission rate of ITP at 6 months after specific cancer treatment
Time Frame: At baseline (Day 0)
At baseline (Day 0)

Secondary Outcome Measures

Outcome Measure
Time Frame
All-cause mortality
Time Frame: At baseline (Day 0)
At baseline (Day 0)
Side effects related to ITP and its treatment
Time Frame: At baseline (Day 0)
At baseline (Day 0)
Side effects related to its treatment
Time Frame: At baseline (Day 0)
At baseline (Day 0)
Clinical description of the characteristics of ITP associated with a diagnosis of solid cancer
Time Frame: At baseline (Day 0)
At baseline (Day 0)
Biological description of the characteristics of ITP associated with a diagnosis of solid cancer
Time Frame: At baseline (Day 0)
At baseline (Day 0)
Demographic description of the characteristics of ITP associated with a diagnosis of solid cance
Time Frame: At baseline (Day 0)
At baseline (Day 0)
Therapeutic description of the characteristics of ITP associated with a diagnosis of solid cance
Time Frame: At baseline (Day 0)
At baseline (Day 0)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Bordeaux

Investigators

  • Principal Investigator: Etienne RIVIERE, MD, University Hospital, Bordeaux

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 13, 2024

Primary Completion (Actual)

September 15, 2025

Study Completion (Actual)

September 15, 2025

Study Registration Dates

First Submitted

May 14, 2024

First Submitted That Met QC Criteria

June 3, 2024

First Posted (Actual)

June 5, 2024

Study Record Updates

Last Update Posted (Actual)

January 26, 2026

Last Update Submitted That Met QC Criteria

January 22, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CHUBX 2024/16

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Neoplasms

Clinical Trials on ITP and cancer

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Japan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe